Key findings from detailed records
A small IBS trial found improvements in selected digestive symptoms with a specific GOS mixture. Of 60 enrolled participants, 44 completed the study. The study lasted 12 weeks overall, with 4-week treatment periods; the tested mixture contained 48% GOS.
KNOWLEDGE RECORD
- Category
- Gut health and dietary fiber
- Last Reviewed
Names and related search termsGOS / Galactooligosaccharides / Galactooligosaccharides / trans-GOS
Study type: human intervention study.
OUTCOME-SPECIFIC EVIDENCE
Scientific Evidence Profile
Assessment pending
An outcome-specific assessment has not yet been completed. This is not a finding that the ingredient is ineffective. The study records below remain available.
This profile concerns the stated outcome and population, not the ingredient as a whole. It is not a probability of benefit, a safety rating, a product efficacy rating or an indication of product adoption.
How we assess evidenceIngredient Profile
- What material is being studied?
- Galacto-oligosaccharides are mixtures of short carbohydrate chains. Enzymes can make them from lactose; the resulting mixture depends on the enzyme and production conditions. [1]
Sources for this profile
Compound properties and formulation properties are different. These sources do not establish the efficacy of a finished supplement.
- Galacto-oligosaccharide production by Lactobacillus delbrueckii ssp. bulgaricus whole cells and lysates. Identity and preparation checked against the study abstract. Funding details are not verified for this profile source. Conflict-of-interest details are not verified here.
Profile sources checked:
Read the evidence in context
- Evidence: what was measured in the stated population or experimental model.
- Inference: an interpretation connecting findings; its applicability depends on the study conditions.
- Hypothesis: a proposed explanation or effect that remains to be tested.
Why It Matters #
How do changes in gut bacteria differ from symptom improvement? Check the detailed records for study conditions and use the literature map to compare other populations and outcomes.
What Was Studied #
44 patients meeting Rome II criteria for IBS completed the trial Randomized controlled trial (single-center, including crossover). Outcomes: Fecal microbiota, stool consistency, abdominal symptoms and global assessment, among other outcomes. Primary outcome hierarchy was not verified in the abstract.[1]
What Was Found #
Bifidobacteria increased. Changes included stool consistency, gas and bloating in the 3.5 g group, and global assessment in the 7 g group.[1]
What the Evidence Means #
Small sample with dose-dependent differences in findings. More bacteria alone does not establish a health benefit.[1]
Comparing similar populations, formulations, durations and outcomes helps identify where findings agree and where they differ.
What We Can Learn #
Assess microbiome composition separately from symptoms and everyday functioning.
What Remains Unknown #
Further questions include reproducibility across populations and formulations, and the long-term balance of benefits and harms. Use the literature map as a starting point for these questions.
LITERATURE MAP / 10 PAPERS
Compare papers by conditions and findings.
A literature map covering different populations, outcomes and formulations. Read alongside detailed records to avoid treating one trial as the conclusion for an entire ingredient.
Selected: 2026-09-21. Bibliographic information checked against Europe PMC / PubMed. Editorial selection considered major papers and a range of populations and questions. This is not a systematic search covering all recent research.
10 RECORDS
A dash marks fields outside the bibliographic record. Use detailed records to compare findings and design records to connect mechanisms.
No papers match. Change the search conditions.
The literature map is an index of research questions and references. Individual assessment of results, doses, funding and COI is limited to the detailed study records. Related reports from the same trial may be included; paper counts are not counts of independent trials.
Explore the research Study Records
Listed doses describe study conditions, not recommended intake.
Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.
PubMed 19053980DOI: 10.1111/j.1365-2036.2008.03911.x
- Authors
- Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR.
- Journal
- Alimentary pharmacology & therapeutics
- Publication year
- 2009
- Study design
- Randomized controlled trial (single-center, including crossover)
- Participants
- 60 enrolled; 44 completed.
- Dose and intervention
- B-GOS mixture 3.5 or 7 g/day (48% GOS), versus placebo.
- Duration
- 12 weeks overall; each treatment period lasted 4 weeks.
- Outcomes and their role in the study
- Fecal microbiota, stool consistency, abdominal symptoms and global assessment, among other outcomes. Primary outcome hierarchy was not verified in the abstract.
- Findings
- Bifidobacteria increased. Changes included stool consistency, gas and bloating in the 3.5 g group, and global assessment in the 7 g group.
- Limitations
- Small sample with dose-dependent differences in findings. More bacteria alone does not establish a health benefit.
- Funding
- Clasado funded the study.
- Conflict of Interest
- Tzortzis was a Clasado employee.
- Scope of source review
- Methods and disclosures checked in a reproduction of the original paper; abstract cross-checked with PubMed.
Cite this page
LÍFSVARÐA. GOS: How do changes in gut bacteria differ from symptom improvement? Version 1.1 / Updated 2026-10-24
https://lifsvarda.com/knowledge/gos/Edited by LÍFSVARÐA (product brand).Editorial policy
Sources and updates
- Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. (2009). Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.Methods and disclosures checked in a reproduction of the original paper; abstract cross-checked with PubMed.
First published: 2026-09-21 / Version 1.1. Updated 2026-09-23: Added a research comparison table and links to design records. Source notes identify the scope of verification when the full paper has not been reviewed. Research summaries and LÍFSVARÐA’s interpretation are distinguished.